Congress Materials – United European Gastroenterology Week (UEGW 2026)
2026 United European Gastroenterology Week | Oct 17-20 | Barcelona, Spain
ARGES-UC V2.0: Artificial Intelligence-Derived Endoscopic Severity Scoring and Disease Characterization in Ulcerative Colitis
Krishna Chaitanya, Natalia Alves, Pooya Mobadersany, Chaitanya Parmar, Louis Ghanem, Camilla Richmond, Els Van Limbergen, Paul J. Ufberg, Richard Strauss, Sheri Volger, Yuliya Halchenko, Nicholas Skomrock, Tommaso Mansi, Gabriela Cula, Kristopher Standish, Pablo F. Damasceno
This document will be available on Oct 20th 2026
Assessment of Inflammatory Bowel Disease-Specific Quality of Life (IMPACT-III) Symptoms After Treatment With Ustekinumab in Pediatric Ulcerative Colitis
Els Van Limbergen, Anne M. Griffiths, Sheri Volger, Lilianne Kim, Gary Mao, Richard Strauss, Paul J. Ufberg, Robert Fieo
This document will be available on Oct 17th 2026
Association of Endoscopic Healing With Clinical Outcomes in Inflammatory Bowel Disease: A Retrospective Study
Elise Wu, Dominik Naessens, Jackie Kwong, Karthik Murugadoss, Sunil Kumar Ravi, Devrata Puri
This document will be available on Oct 17th 2026
Changes in Intestinal Stenosis Among Patients With Moderately to Severely Active Crohn’s Disease Treated With Guselkumab: Results From the Phase 3 GALAXI and GRAVITI Studies
Walter Reinisch, Anita Afzali, Hamid Bassiri, Rian Van Rampelbergh, Wilbert van Duijnhoven, Shashi Adsul, Dylan J. Richards, Nat A. Terry, David T. Rubin, on behalf of the GALAXI and GRAVITI Investigators
This document will be available on Oct 18th 2026
Computer-Vision Assessment of Endoscopic Disease Severity in Subjects With and Without Prior Exposure to Advanced Therapies Across Adult and Pediatric Ulcerative Colitis Clinical Trials
Natalia Alves, Krishna Chaitanya, Pooya Mobadersany, Chaitanya Parmar, Louis Ghanem, Camilla Richmond, Els Van Limbergen, Paul J. Ufberg, Richard Strauss, Sheri Volger, Nicholas Skomrock, Gabriela Cula, Kristopher Standish, Pablo F. Damasceno
This document will be available on Oct 17th 2026
Deep Remission in Guselkumab-Treated Participants With Moderately to Severely Active Crohn’s Disease Through 3 Years: Results From the GALAXI 2 & 3 Studies
David T. Rubin, Anita Afzali, Christopher Busse, Rian Van Rampelbergh, Wilbert van Duijnhoven, Marla Dubinsky, Geert R. D’Haens
This document will be available on Oct 19th 2026
Early Improvement of Inflammatory Biomarkers Predicts 1-Year Outcomes in Adults With Crohn’s Disease Treated With Guselkumab: Pooled GALAXI 2 & GALAXI 3, Phase 3 Trials Analysis
Marc Ferrante, Alessandro Armuzzi, Raja Atreya, Tim Raine, Rian Van Rampelbergh, Jacqueline van Denderen, Maciej Nazar, Victoria McCaffrey, Mathurin Fumery
This document will be available on Oct 18th 2026
Early Symptomatic Response to Guselkumab in Inflammatory Bowel Disease: First Real-World Data From the German GORGEOUS Study
Stefan Schubert, Robert Ehehalt, Wilfried Landry, Christoph Jochum, Elisabeth Schnoy, Fabian Kreimendahl, Terry-Lisa Ly, Eva Hundt, Kathleen Vogel, Lukas Scharfenberger
This document will be available on Oct 17th 2026
Efficacy and Safety of Guselkumab in Perianal Fistulizing Crohn’s Disease: Week 48 Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled FUZION Trial
Ailsa Hart, Axel Dignass, Vipul Jairath, Tadakazu Hisamatsu, Bruce E. Sands, Antonino Spinelli, Susan J. Connor, André D’Hoore, Walter Reinisch, Silvio Danese, David A. Schwartz, Julian Panés, Bram Verstockt, Anton Stift, Maciej Nazar, Jacqueline van Denderen, Takehiko Sakamoto, Koji Masuda, Stephen Xu, Ivana Bravatà, Geert D’Haens, Laurent Peyrin-Biroulet, on behalf of the FUZION Study Group
This document will be available on Oct 19th 2026
Efficacy and Safety of Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 144 From the Phase 3 GALAXI 2 & 3 Studies
Bruce E. Sands, Walter Reinisch, Geert R. D’Haens, Remo Panaccione, Anita Afzali, David T. Rubin, Jacqueline Yee, Wilbert van Duijnhoven, Christopher Corbett, Rian Van Rampelbergh, Tadakazu Hisamatsu, Silvio Danese
This document will be available on Oct 19th 2026
Efficacy and Safety of the First Co-Antibody Therapy, JNJ-78934804, in Patients With Moderately to Severely Active Crohn’s Disease Refractory to Two or More Systemic Therapy Mechanisms
Vipul Jairath, Geert R. D’Haens, Iris Dotan, Nat A. Terry, Monica Walker, Vanessa Bundy, Hayley Perry, Dylan Richards, Marion L. Vetter, Taku Kobayashi, Stefan Schreiber, Bruce E. Sands
This document will be available on Oct 19th 2026
Efficacy and Safety of the First Co-Antibody Therapy, JNJ-78934804, in Patients With Moderately to Severely Active Ulcerative Colitis Refractory to Two or More Systemic Therapy Mechanisms
Raja Atreya, Bruce E. Sands, Séverine Vermeire, Remo Panaccione, Gregory T. Moore, John Lynch, Melissa G. Marko, Eun Suk Jung, Ruchi Patel, Siyka Alexandrova, Hayley Perry, Marion L. Vetter, Julián Panés, Maria T. Abreu
This document will be available on Oct 20th 2026
Endoscopic Outcomes of Ulcer Size and Ulcerated Surface Over One Year Across Bowel Segments in Participants With Crohn’s Disease Treated With Guselkumab: Pooled GALAXI 2 and GALAXI 3, Phase 3 Trials Analysis
Alessandro Armuzzi, Mathurin Fumery, Bruce E. Sands, Marc Ferrante, Tim Raine, Rian Van Rampelbergh, Maciej Nazar, Victoria McCaffrey, Jacqueline van Denderen, Raja Atreya
This document will be available on Oct 20th 2026
Guselkumab Efficacy in Subgroups of Adults With a History of Inadequate Response or Intolerance to Anti-Tumor Necrosis Factor-Α Therapy and Moderately to Severely Active Crohn’s Disease: Results From the GALAXI 2 & 3 Studies
Walter Reinisch, Remo Panaccione, Geert D, Haens, Tadakazu Hisamatsu, Bruce E Sands, Rian Van Rampelbergh, Wilbert van Duijnhoven, Shashi Adsul, Gustavo Scapini, Silvio Danese, Anita Afzali
This document will be available on Oct 18th 2026
Histologic and Endoscopic Efficacy of Icotrokinra, A First-in-Class Targeted Oral Peptide That Precisely Blocks the IL-23 Receptor, in Ulcerative Colitis: Outcomes From the ANTHEM-UC Study
Britta Siegmund, Jimmy K. Limdi, Edward V. Loftus, Jr., Vipul Jairath, Maria T. Abreu, Minhu Chen, Edouard Louis, Katsuyoshi Matsuoka, Lindsey Surace, Ngozi Erondu, Martha Zeeman, Joyce Zhan, Mary Ellen Frustaci, Grazyna Rydzewska, Karen Chachu
This document will be available on Oct 20th 2026
Imaging Practices and Use of Intestinal Ultrasound For Moderate-to-Severe Inflammatory Bowel Disease: A Multinational Physician Survey in China, Japan, and Germany
Katsuyoshi Matsuoka, Hong Yang, Xiaoxiao Alice Lu, Bo Chen, Ayako Sasaki, Ursula Kleine-Vossbeck, Shashi Adsul, Tiange Liu, Meshal Imran, Yan Wang, Shimin Bi, Han Gao, Rouven Hecht, Lukas Scharfenberger, Keira Herr, Ivana Bravata, Darren Pscitelli, Claudia Ott, Irina Blumenstein
This document will be available on Oct 18th 2026
Pharmacokinetics and Exposure-Response Relationships of Subcutaneous Guselkumab Maintenance in Participants With Moderately to Severely Active Crohn’s Disease
Bruce E. Sands, Geert R. D’Haens, Omoniyi J. Adedokun, Tae Eun Yang, David T. Rubin, Nat A. Terry, Rian Van Rampelbergh, Marion L. Vetter, Tadakazu Hisamatsu, Remo Panaccione, Silvio Danese
This document will be available on Oct 20th 2026
Pharmacokinetics and Exposure-Response Relationships of Subcutaneous Guselkumab Maintenance in Participants With Moderately to Severely Active Ulcerative Colitis
David T. Rubin, Laurent Peyrin-Biroulet, Jie Shao, Yu Kyoung Cho, Jafar Sadik B. Shaik, Millie Long, Silvio Danese, Yelina Alvarez, Marion L. Vetter, Thomas Baker, Jessica R. Allegretti, Tadakazu Hisamatsu
This document will be available on Oct 20th 2026
Physician Opinions on Treatment Preferences and Long-Term Treatment Goals For Moderate-to-Severe Inflammatory Bowel Disease in China, Japan, and Germany
Irina Blumenstein, Hong Yang, Xiaoxiao Alice Lu, Bo Chen, Ayako Sasaki, Ursula Kleine-Vossbeck, Shashi Adsul, Tiange Liu, Meshal Imran, Jia Zhong, Aolin Wang, Han Gao, Rouven Hecht, Lukas Scharfenberger, Keira Herr, Ivana Bravata, Darren Pscitelli, Claudia Ott, Katsuyoshi Matsuoka
This document will be available on Oct 17th 2026
Physician Opinions on Treatment Preferences and Long-Term Treatment Goals in Moderate to Severe Ulcerative Colitis and Crohn’s Disease in Germany
Irina Blumenstein, Xiaoxiao Alice Lu, Ursula Kleine-Vossbeck, Shashi Adsul, Yichen Zhang, Meshal Imran, Jessica Smith, Aolin Wang, Rouven Hecht, Lukas Scharfenberger, Julian Pohlan, Ivana Bravata, Darren Piscitelli, Claudia Ott
This document will be available on Oct 17th 2026
Plasma, Colon Tissue and Fecal Pharmacokinetics of Icotrokinra in ANTHEM-UC: Results Through Week 28 From a Phase 2B Dose-Ranging Study in Ulcerative Colitis Patients
Tristan Baguet, Lindsey Surace, Joyce Zhan, Ngozi Erondu, Mary Ellen Frustaci, Colleen Marano, Vipul Jairath, Maria T. Abreu, Britta Siegmund, An Vermeulen
This document will be available on Oct 17th 2026
Regulation of Fibroblast Biology in Ileum and Rectum By Guselkumab in Crohn’s Disease: Post-Hoc Analysis of GALAXI Ph3 Program
Dylan J. Richards, Patrick Branigan, Hamid Bassiri, Rian Van Rampelbergh, Nat A. Terry, Bradford McRae
This document will be available on Oct 17th 2026
Single-Cell and Spatial Profiling of Cellular Composition and Signaling Changes Following Icotrokinra Treatment in Ulcerative Colitis: Results From ANTHEM-UC
Klebea Sohn, Joshua Rusbuldt, Lynn Tomsho, Daniel Horowitz, Jared Liu, Koichi Hashikawa, Koen Van den Berge, Ewoud De Troyer, Roohid Parast, Martha Zeeman, Lindsey Surace, Ngozi Erondu, Colleen Marano, Dawn Waterworth, Brad McRae, Amy Hart, Arun Kannan, Britta Seigmund, Edouard Louis, Maria T. Abreu
This document will be available on Oct 20th 2026
The Efficacy and Safety of Guselkumab in Patients With Moderate to Severe Ulcerative Colitis Through 2 Years: ASTRO Week 96 Results
Millie Long, Laurent Peyrin-Biroulet, Tadakazu Hisamatsu, Jessica R. Allegretti, Yelina Alvarez, Thomas Baker, Karen Hertzog, Chenglong Han, Hongyan Zhang, Ye Miao, David T. Rubin, Silvio Danese
This document will be available on Oct 18th 2026
Unsupervised Machine Learning to Identify Distinct Patient-Level Response Patterns to Guselkumab in Ulcerative Colitis: Post Hoc Analysis From the ASTRO Trial
Stefan Schreiber, Silvio Danese, Sudheer Rani, Thomas Baker, Yelina Alvarez, Long-Long Gao, Zijiang Yang, Timothy Hoops, Millie Long
This document will be available on Oct 17th 2026
Ustekinumab Exposure During Pregnancy and Risk of Small For Gestational Age in Inflammatory Bowel Disease: Results From the DUMBO Registry of GETECCU
María Chaparro, Ana Garre, Ainhoa Aranguren, Eduardo Leo Carnerero, Cristina Calviño-Suárez, María Dolores Martín Arranz, Marta Calvo, Lucía Zabalba San Martín, Isabel Pérez Martínez, Maite Arroyo, Agnes Fernández-Clotet, Sandra Marín Pedrosa, María Teresa Diz-Lois Palomares, María José Casanova, Vicent Hernández Ramírez, Montserrat Rivero, Alexandra Ruiz Cerulla, Pilar Corsino Roche, José María Huguet, Iván Guerra, Lara Arias, Raquel Camargo Camero, Gemma Valldosera, Ana Bejarano García, Ana Gutiérrez Casbas, Ángeles Masedo, Daniel Hervías, Iago Rodríguez Lago, Miguel Ángel de Jorge, Daniel Ceballos, Luis Bujanda, Pilar López Serrano, Mariam Aguas, Ana Echarri Piudo, Manuel Van Domselaar, Alfredo Lucendo, Carlos Tardillo Marín, Pablo Vega, Marta Maia Boscá Watts, David Busquets Casals, Marta Piqueras Cano, Virginia Robles Alonso, Edisa Mª Armesto González, Beatriz Zuñiga de Mora-Figueroa, Miriam Mañosa, Pau Sendra Rumbeu, Esther Bernardos, Lucía Márquez Mosquera, Patricia Ramírez de La Piscina Urraca, Mari Carmen Rodríguez Grau, Noemí Manceñido, Vanesa Prieto, Laura Ramos, Wendy Xiomara Ladino, Víctor Manuel Navas López, Mª Rocío Plaza Santos, María Curieses, Empar Sainz Arnau, Elena Betoré Glaría, Carlos Castaño Milla, Miguel Sans Cuffi, Antonio García Herola, Gisela Torres Vicente, Sandra Hermida, Nuria Montes, Javier P. Gisbert
This document will be available on Oct 19th 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.